Literature DB >> 7285478

Prazosin dynamics in hypertension: relationship to plasma concentration.

P Seideman, A Grahnén, K Haglund, B Lindström, C von Bahr.   

Abstract

The antihypertensive effects of prazosin in relation to its kinetics were studied after single doses (intravenous and oral, 0.5 mg) and during increasing multiple doses (0.5 to 5 mg three times a day). There was a fall in systolic and diastolic blood pressures of 10% to 14%, which was greater in the standing than in the sitting position. Prazosin plasma concentrations correlated with dose (P less than 0.001). After intravenous prazosin the fall in systolic and diastolic blood pressure and prazosin plasma concentration correlated (P less than 0.01) during the beta-elimination phase in all patients. In only five of eight patients, however, did mean plasma concentration and antihypertensive effect during continuous treatment with different doses correlate. The maximal fall in systolic blood pressure correlated (P less than 0.01) with that after the first oral steady-state dose (0.5 mg three times daily), which indicates limited possibility of early identification of prazosin responders. There were no signs of overshoot of blood pressure when prazosin was withdrawn for a week. On rechallenge with a single oral dose of 2.5 mg prazosin there were no signs of enhanced hypotensive effect.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7285478     DOI: 10.1038/clpt.1981.187

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

2.  Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: I. Effects on blood pressure, heart rate and pressor responsiveness in normotensive subjects.

Authors:  R F Schafers; H L Elliott; C A Howie; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

3.  Concentration-effect relationships and individual responses to doxazosin in essential hypertension.

Authors:  R Donnelly; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

4.  Responsiveness of superficial hand veins to phenylephrine in essential hypertension. Alpha adrenergic blockade during prazosin therapy.

Authors:  H G Eichler; G A Ford; T F Blaschke; A Swislocki; B B Hoffman
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

5.  Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients.

Authors:  P Seideman; A Grahnén; K Haglund; B Lindström; C Von Bahr
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

6.  Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man.

Authors:  J Vincent; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

7.  Intraindividual comparison of moxonidine and prazosin in hypertensive patients.

Authors:  V Plänitz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of prazosin--1985.

Authors:  J Vincent; P A Meredith; J L Reid; H L Elliott; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 9.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.